(NASDAQ: MYGN) Myriad Genetics's forecast annual revenue growth rate of 3.4% is not forecast to beat the US Diagnostics & Research industry's average forecast revenue growth rate of 7.69%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 13.9%.
Myriad Genetics's revenue in 2026 is $806,600,000.On average, 12 Wall Street analysts forecast MYGN's revenue for 2026 to be $75,886,515,350, with the lowest MYGN revenue forecast at $72,430,693,676, and the highest MYGN revenue forecast at $78,738,787,764. On average, 12 Wall Street analysts forecast MYGN's revenue for 2027 to be $80,115,186,156, with the lowest MYGN revenue forecast at $75,505,829,763, and the highest MYGN revenue forecast at $84,875,668,987.
In 2028, MYGN is forecast to generate $85,530,869,055 in revenue, with the lowest revenue forecast at $77,833,942,122 and the highest revenue forecast at $94,004,471,106.